logo-loader
viewMotif Bio PLC

Motif closes in on approvals, potentially looking for partnership opportunities

US food and drug administration approval isn't there yet, but Motif continues to chug forwards

1524140870_ampoules.jpg
Motif Bio is evaluating commercialisation options

In the world of US drug approvals, a positive result in a Phase 3 drug trial is generally celebrated with flourish: it might feel like you are nearing the end of the track. The finish line is near. One might think you're in the clear.

But it's not quite that simple.

WATCH: Motif Bio evaluating commercialisation options as decision time approaches

As Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB) knows all too well, getting a drug to market is no small task. The company is focused on a best-in-class drug, iclaprim, that targets bacteria resistant to most other commonly used antibiotics.

“Were spending a lot of time thinking about how we come to market in the US…” said Lumsden.  “We’re having some very constructive conversations with some potential partners.”

A potential partnership could be beneficial for Motif, from an efficiency and capital standpoint.

Major milestones achieved, more to come

Motif faces more work in the coming months as it continues to push towards final approval.

It passed a major milestone last year when it concluded a second phase III clinical trial on iclaprim and initiated a rolling submission to the US Food and Drug Administration, while also preparing a marketing authorization application to the European Medicines Agency. The submission is expected to be completed in the second quarter of 2018.

Potential partnerships

One question looming on Lumsden’s mind is figuring out the best way to come to market in the US. Should Motif go at it alone, or alongside a partner?

Lumsden says there are many paths Motif could go down: from a co-promotion effort, a licensing deal, or even a full M&A transaction.

“It’s our preferred path to try to find a partner for the US market,” said Lumsden. “If we have to do it ourselves, we can, we will, we just don’t think it’s the optimal way to do it.”

Lumsden stresses that in these types of situations, it can be far more effective and efficient to partner up. Potentially, that could be with another company that also has a single asset, perhaps in this case, a gram-negative antibiotic, which could complement nicely with iclaprim, which is a gram-positive antibiotic. However, all options are still on the table.

“We’re anticipating a decision, hopefully an approval from the FDA, in the first quarter [2019],” said Lumsden.

Medical science liaisons to play important role

About about six months ahead of the potential approval, there will likely be a push to increase awareness of iclaprim in both the medical community and hospital formulary committees. Generally, this is done by a team of medical science liaisons (MSLs), who use the scientific literature as an educational tool. In the case of Motif, it may make sense to team up with another partner, when it comes to forming the MSL team. Most people expect a decision on this to be made by the third quarter.

Beneficial for those with impaired kidneys

Iclaprim is a gram-positive antibiotic targeted especially to those who may have impaired kidneys, and/or face other compromising factors, such as diabetes. It is estimated that up to 26% of the 3.6mln patients hospitalized annually with acute bacterial skin and skin structure infections have kidney disease.

READ: Home plate beckons for Motif Bio

Antibiotics are the most commonly prescribed class of drug, representing a global market of $40bln. New, innovative approaches are needed, due to ever-evolving drug-resistant strains of bacteria.  

The numbers:

Motif just released their financial results for the year, which showed the company spent US$29.5mln on research and development -- a reflection of the work it has completed in clinical trials ahead of the regulatory application for iclaprim. Upon approval, iclaprim will be eligible for 10 years of market exclusivity in the US, starting from the date of first approval.

From a cash perspective, the figure was substantially down year-over-year, reflecting the high cost of getting a drug to market, which was US$34.8mln, and more importantly, Motif was sitting on US$22.7mln of cash at the year-end with access to US$20mln of debt financing.

Global and US opportunity looks bright

The global market for antibiotic drugs targeting difficult-to-treat infections, such as iclaprim, is an estimated US$3.0bln and is dominated by vancomycin, a traditional first-line treatment.

From an approval perspective, the future looks bright, compared to a stagnant few decades. From 2003 to 2010, only one new antibiotic was approved by the US Food and Drug Administration (FDA), and 10 since 2010. However, this year the FDA could approve as many as half a dozen new drugs, all from small players, such as Motif.

READ: Motif Bio to present new Iclaprim safety and efficacy data at top European conference

This weekend, Motif will present data at the 28th European Congress of Clinical Microbiology and Infectious Diseases which shows iclaprim still works on a variety of antibiotic-resistant pathogens such as methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) Staphylococcus aureus.

Quick facts: Motif Bio PLC

Price: 0.61 GBX

AIM:MTFB
Market: AIM
Market Cap: £2.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018

RNS

Second Price Monitoring Extn

1 day, 11 hours ago

Price Monitoring Extension

1 day, 11 hours ago

Second Price Monitoring Extn

2 weeks, 5 days ago

Price Monitoring Extension

2 weeks, 5 days ago

Change of Adviser

2 weeks, 5 days ago

Conditional Placing

2 weeks, 6 days ago

5 min read